Jeffrey Brian Locke

Dr. Jeffrey Brian Locke

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
DSDaniel F. Sahm
Daniel F. Sahm
JDJennifer Deane
Jennifer Deane
PBPaul A. Bien
Paul A. Bien
JLJeffrey Brian Locke
Jeffrey Brian Locke
DZDouglas E. Zuill
Douglas E. Zuill
KBKen F. Bartizal
Ken F. Bartizal

1 October 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JLJeffrey Brian Locke
Jeffrey Brian Locke
AAAmanda L. Almaguer
Amanda L. Almaguer
DZDouglas E. Zuill
Douglas E. Zuill
KBKen Bartizal
Ken Bartizal
CD101 is a novel echinocandin with a long half-life undergoing clinical development for treatment of candidemia/invasive candidiasis and vulvovaginal candidiasis. The potential for and mechanisms underlying the development of resistance to CD101 in Candida species were investigated by using spontaneous resistance and serial passage selection methodologies. Four Candida spp. ( C. albicans , C. glabrata , C. parapsilosis , and C. krusei ) were chosen for resistance characterization with CD101, anidulafungin, and caspofungin. The frequency of spontaneous, single-step mutations conferring reduced susceptibility to CD101 at 1× the agar growth inhibition concentration was low across all species, with median frequencies ranging from 1.35 × 10 −8 to 3.86 × 10 −9 , similar to ranges generated for anidulafungin and caspofungin. Serial passage of Candida spp. on agar plates containing drug gradients demonstrated a low potential for resistance development, with passage 20 CD101-selected strains possessing increases in MICs equivalent to or lower than those for the majority of strains generated under selection with anidulafungin and caspofungin. A total of 12 fks “hot spot” mutations were identified, typically in strains with the highest MIC shifts. Cross-resistance was broadly observed among the 3 echinocandins evaluated, with no CD101-selected mutants (with or without fks hot spot mutations) exhibiting reduced susceptibility to CD101 but not also to anidulafungin and/or caspofungin. Consistent with currently approved echinocandins, CD101 demonstrates a low potential for resistance development, which could be further enhanced in vivo by the high maximum concentration of drug in serum ( C max )/area under the concentration-time curve (AUC) plasma drug exposure achieved with once-weekly dosing of CD101.

16 April 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
Renato KovacsRenato Kovacs
Renato Kovacs
TZTóth Zoltán
Tóth Zoltán
JLJeffrey Brian Locke
Jeffrey Brian Locke
LFLajos Forgács
Lajos Forgács
GKGábor Kardos
Gábor Kardos
Laszlo MajorosLaszlo Majoros
Laszlo Majoros
Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates representing four C. auris clades (South Asian n = 3; East Asian n = 3; South African n = 3; South American n = 4, of which two were of environmental origin). Minimum inhibitory concentration MICs and killing kinetics in RPMI-1640 and RPMI-1640 plus 50% serum (50% serum) were determined. The four echinocandins were never fungicidal and induced large aggregates in RPMI-1640 and, less markedly, in 50% serum. Colony forming unit CFU decreases were found more consistently in 50% serum than in RPMI-1640. Isolates from the East Asian clade were killed at ≥1–≥ 4 mg/L with all echinocandins regardless of media. Anidulafungin and micafungin produced killing at peak drug serum concentration (8 mg/L) against environmental but not clinical isolates from the South American and the South African clades. Micafungin at ≥8 mg/L but not anidulafungin produced CFU decreases against the South Asian clade as well. In 50% serum, rezafungin at ≥1–≥ 8 mg/L produced killing against all four clades. The next generation echinocandin, rezafungin, showed the same or better activity at clinically attainable trough concentration regardless of media, compared with anidulafungin, caspofungin, and micafungin against all four tested C. auris clades.

3 February 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
DBDina A. Boikov
Dina A. Boikov
JLJeffrey Brian Locke
Jeffrey Brian Locke
KJKenneth D. James
Kenneth D. James
KBKen Bartizal
Ken Bartizal
JSJack D. Sobel
Jack D. Sobel
Background: The novel echinocandin CD101 has stability properties amenable to topical formulation for use in the treatment of acute vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC). CD101 has demonstrated potent antifungal activity at pH 7, but assessment of its activity at the physiological pH of the vaginal environment is needed. Objectives: To evaluate the antifungal activity of CD101 against clinical VVC isolates of Candida spp., including azole-resistant strains, at pH 4. Methods: MIC values of CD101 and comparators (fluconazole, itraconazole, micafungin, caspofungin and anidulafungin) were assessed via broth microdilution. MIC assays were conducted at pH 7 and 4 after 24 and 48 h against a 108 VVC isolate panel of Candida spp., including Candida albicans (n = 60), Candida glabrata (n = 21), Candida parapsilosis (n = 14) and Candida tropicalis (n = 13). Results: Overall, MIC values of all drugs were slightly higher at pH 4 versus 7 and at 48 versus 24 h of incubation. CD101 MIC values typically exhibited ∼4-fold shifts at pH 4 and were not affected by azole susceptibility. C. parapsilosis susceptibility was the least affected at pH 4 and did not increase for most drugs. Conclusions: CD101 had potent activity against all Candida isolates tested, including azole-resistant strains. Although there was some reduction in activity at pH 4 versus 7, the resulting MIC values were still well below the intravaginal CD101 drug concentrations anticipated to be present following topical administration. These results support continued development of topical CD101 for the treatment of VVC/RVVC.

1 November 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JLJeffrey Brian Locke
Jeffrey Brian Locke
DZDouglas E. Zuill
Douglas E. Zuill
CSCaitlyn R. Scharn
Caitlyn R. Scharn
JDJennifer Deane
Jennifer Deane
DSDaniel F. Sahm
Daniel F. Sahm
KSKaren J. Shaw
Karen J. Shaw
The Cfr methyltransferase confers resistance to six classes of drugs which target the peptidyl transferase center of the 50S ribosomal subunit, including some oxazolidinones, such as linezolid (LZD). The mobilecfrgene was identified in European veterinary isolates from the late 1990s, although the earliest report of a clinicalcfr-positive strain was the 2005 Colombian methicillin-resistantStaphylococcus aureus(MRSA) isolate CM05. Here, through retrospective analysis of LZDrclinical strains from a U.S. surveillance program, we identified acfr-positive MRSA isolate, 1128105, from January 2005, predating CM05 by 5 months. Molecular typing of 1128105 revealed a unique pulsed-field gel electrophoresis (PFGE) profile most similar to that of USA100,spatype t002, and multilocus sequence type 5 (ST5). In addition tocfr, LZD resistance in 1128105 is partially attributed to the presence of a single copy of the 23S rRNA gene mutation T2500A. Transformation of the ∼37-kb conjugative p1128105cfr-bearing plasmid from 1128105 intoS. aureusATCC 29213 background strains was successful in recapitulating the Cfr antibiogram, as well as resistance to aminoglycosides and trimethoprim. A 7-kbcfr-containing region of p1128105 possessed sequence nearly identical to that found in the Chinese veterinaryProteus vulgarisisolate PV-01 and in U.S. clinicalS. aureusisolate 1900, although the presence of IS431-like sequences is unique to p1128105. Thecfrgene environment in this early clinicalcfr-positive isolate has now been identified in Gram-positive and Gram-negative strains of clinical and veterinary origin and has been associated with multiple mobile elements, highlighting the versatility of this multidrug resistance gene and its potential for further dissemination.

2 May 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
JLJeffrey Brian Locke
Jeffrey Brian Locke
CPChris M. Pillar
Chris M. Pillar
MCMariana G Castanheira
Mariana G Castanheira
CCCecilia G. Carvalhaes
Cecilia G. Carvalhaes
DADavid Andes
David Andes
PPPeter G. Pappas
Peter G. Pappas
Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline Candida species is described. Susceptibility testing was performed for Candida species using the Clinical and Laboratory Standards Institute reference broth microdilution method. There were 93 patients in the modified intent-to-treat population who received rezafungin; 94 received caspofungin. Baseline Candida species distribution was similar in the two treatment groups; C. albicans (occurring in 41.9% and 42.6% of patients in the rezafungin and caspofungin groups, respectively), C. glabrata (25.8% and 26.6%), and C. tropicalis (21.5% and 18.1%) were the most common pathogens. Rates of global cure and mycological eradication at day 14 and day 30 all-cause mortality by Candida species were comparable in the rezafungin and caspofungin treatment groups and did not appear to be impacted by minimal inhibitory concentration (MIC) values for either rezafungin or caspofungin. Two patients had baseline isolates with non-susceptible MIC values (both in the rezafungin group: one non-susceptible to rezafungin and one to caspofungin, classified as intermediate); both were candidemia-only patients in whom rezafungin treatment was successful based on the day 30 all-cause mortality endpoint. This analysis of ReSTORE demonstrated the efficacy of rezafungin for candidemia and IC in patients infected with a variety of Candida species.